Abstract
Yu and colleagues ([1][1]) assessed the pharmacogenomics profiling (PGx) of circulating tumorigenic and invasive cells to stratify/predict treatment response in pancreatic ductal adenocarcinoma (PDAC). They suggested the PGx assay as an appropriate tool for choosing a potentially effective targeted
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
